查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715649

生物製药辅料市场（按产品、供应商、配方类型和最终用户划分）—2025-2030 年全球预测

Biopharmaceutical Excipients Market by Product, Source, Formulation Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年生物製药辅料市场价值将达到 36.1 亿美元，2025 年将成长至 39.6 亿美元，复合年增长率为 9.69%，到 2030 年将达到 63 亿美元。

主要市场统计数据
基准年2024年 36.1亿美元
预计2025年 39.6亿美元
预测年份 2030 63亿美元
复合年增长率（%） 9.69%

生物製药辅料已成为现代治疗方法中的关键成分，不仅提供了输送活性药物成分的手段，还提供了增强稳定性、生物有效性和患者依从性的解决方案。随着时间的推移，赋形剂已经从单纯的惰性载体演变为对产品性能做出积极贡献的载体。这项变更是由科学和工程技术的进步所推动的，从而产生了符合严格品质标准和监管要求的更精密的材料。当前的市场环境反映了强大的研究计划和动态技术发展的交汇，改进的製造流程和创新的成分设计重新定义了治疗应用。此外，化学工程师、生物製药科学家和製造工程师之间的持续合作正在推动该领域的下一波创新。因此，相关人员现在可以更好地平衡疗效和安全性，为满足患者需求的复杂治疗方法和高度专业化的药物铺平道路。本书全面分析了市场动态、特定细分市场的细微差别以及在快速发展的竞争环境中指导产业参与者的策略必要事项。

生物製药辅料格局的变革

由于市场动态对创新、效率和法规遵循产生前所未有的影响，生物製药辅料格局正在变革时期。快速的技术进步和增强的生产实践促进了更纯净、更具功能性的化合物的产生，提高了产品性能，同时确保满足严格的品质标准。人们明显地从传统的化学衍生成分转向结合先进聚合物科学和增强生物活性特性的新型配方。随着企业努力平衡经济成长与环境责任，永续采购和转向更环保的生产方法的转变也成为关注的焦点。这一演变得益于强大的研发投入以及与全球研究机构和产业先驱的策略合作，这些合作共同促进了多学科见解，以优化赋形剂的功能。此外，人们对个人化医疗和精准药物输送的日益关注导致配方的重新设计，以针对特定的治疗方式和患者群体。这些颠覆性趋势为以不断创新和适应性策略为特征的市场发展奠定了基础，从根本上改变了辅料对药物开发的贡献方式。因此，该行业将找到对长期成功至关重要的差异化、成本效益和改善患者结果的机会。

详细的市场分析与市场细分

详细的細項分析揭示了全面而动态的生物製药辅料市场的多方面方法。从以产品为基础的细分角度来看，市场可分为粘合剂、被覆剂、稀释剂、崩坏、润滑剂和助流剂、多元醇、防腐剂、增溶剂、界面活性剂/乳化剂、悬浮剂和黏度剂等专业领域。透过对粘合剂的细分，例如纤维素粘合剂、羟丙基甲基纤维素 (HPMC)、聚维酮 (聚乙烯吡咯烷酮或 PVP)、淀粉和改性淀粉，实现了进一步的特殊性。同样，人们研究了各种类型的包衣，包括控制释放、肠溶包衣、薄膜包衣、密封包衣和糖衣包衣，稀释剂包括磷酸钙、乳糖和结晶纤维素。在多元醇领域，重点是甘露醇和山梨醇，而增溶剂和界面活性剂/乳化剂进一步分为酯、聚山梨醇酯和甘油三酯。此外，基于来源的细分区分了天然辅料和合成辅料。此外，依製剂类型细分，注射剂型包括肌肉注射、静脉注射和皮下注射，口服剂型包括胶囊、粉末和锭剂，局部剂型包括乳膏、凝胶、软膏和洗剂。最后，最终用户细分涵盖生物製药公司、製药公司、契约製造和研究机构，所有这些细分都被综合起来，以提供对整个市场动态范围的详细了解。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 慢性病的流行使得全球对先进的药物製剂的需求增加。
      • FDA 对生物製药辅料的核准和调查活动增加
      • 人们对多功能赋形剂的兴趣日益浓厚，以增强药物稳定性和疗效
    • 限制因素
      • 开发成本高导致仿冒品添加剂流通
    • 机会
      • 支持聚合物药物的创新辅料研发快速成长
      • 伙伴关係和合作关係，加强辅料供应链和分销
    • 任务
      • 生物製药产业辅料合规性的复杂性
  • 市场区隔分析
    • 产品：多元醇在增强生物製药配方稳定性和功能性方面的多种作用
    • 剂型：口服製剂越来越多地使用赋形剂来确保内容物的稳定性
    • 资料来源：由于天然添加剂具有生物相容性和可再生，人们对其的兴趣日益浓厚
    • 最终用户：生物製药和製药公司在创新药物配方中越来越多地使用赋形剂
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章生物製药辅料市场（依产品）

  • 黏合剂
    • 纤维素黏合剂
    • 羟丙基甲基纤维素（HPMC）
    • 聚维酮（聚乙烯吡咯烷酮或 PVP）
    • 淀粉和改性淀粉
  • 涂层
    • 控释包衣
    • 肠溶衣
    • 薄膜包衣
    • 密封涂层
    • 糖霜
  • 冲淡
    • 磷酸钙
    • 乳糖
    • 结晶纤维素
  • 崩坏
  • 润滑剂和润滑剂
  • 多元醇
    • 甘露醇
    • 山梨糖醇
  • 防腐剂
  • 增溶剂和界面活性剂/乳化剂
    • 酯
    • 聚山梨醇酯
    • 三酸甘油酯
  • 悬浮剂和增稠剂

第七章生物製药辅料市场（依来源）

  • 天然辅料
  • 合成辅料

第 8 章：生物製药辅料市场（依配方种类）

  • 注射
    • 肌肉注射
    • 静脉
    • 皮下
  • 口服製剂
    • 胶囊
    • 粉末
    • 药片
  • 局部製剂
    • 奶油
    • 凝胶和软膏
    • 洗剂

第九章生物製药辅料市场（依最终用户）

  • 生物製药和製药公司
  • 契约製造
  • 研究组织

第 10 章：美洲生物製药辅料市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太生物製药辅料市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 12 章欧洲、中东和非洲生物製药辅料市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • ABITEC Corporation
  • Actylis
  • Asahi Kasei Corporation
  • Ashland Inc.
  • Avantor, Inc.
  • BASF SE
  • Clariant International Ltd.
  • Colorcon Ltd.
  • Croda International PLC
  • DFE Pharma GmbH & Co KG
  • Eastman Chemical Company
  • Evonik Industries AG
  • Fuji Chemical Industries Co., Ltd.
  • IMCD NV
  • Innophos Holdings, Inc.
  • International Flavors & Fragrances Inc.
  • JRS PHARMA GmbH+Co. KG
  • Kerry Group PLC
  • Meggle Group GmbH
  • Merck KGaA
  • Mitsubishi Chemical Group Corporation
  • NOF Corporation
  • Novo Nordisk A/S
  • Pfanstiehl, Inc.
  • Roquette Freres SA
  • Shin-Etsu Chemical Co., Ltd.
  • Sigachi Industries Limited
  • Spectrum Laboratory Products, Inc.
  • SPI Pharma, Inc. By Associated British Foods
  • The Archer-Daniels-Midland Company
  • The Dow Chemical Company
  • The Lubrizol Corporation
  • Wacker Chemie AG
Product Code: MRR-A339DAEFAD78

The Biopharmaceutical Excipients Market was valued at USD 3.61 billion in 2024 and is projected to grow to USD 3.96 billion in 2025, with a CAGR of 9.69%, reaching USD 6.30 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 3.61 billion
Estimated Year [2025] USD 3.96 billion
Forecast Year [2030] USD 6.30 billion
CAGR (%) 9.69%

Biopharmaceutical excipients have emerged as critical components in the formulation of modern therapies, offering not only the means to deliver active pharmaceutical ingredients but also solutions that enhance stability, bioavailability, and patient compliance. Over time, excipients have evolved from mere inert carriers to active contributors to product performance. This transformation has been driven by advancements in both science and engineering, leading to more sophisticated materials that meet stringent quality standards and regulatory requirements. The current market landscape reflects an intersection of robust research initiatives and dynamic technological developments, where improved manufacturing processes and innovative ingredient design are redefining therapeutic applications. Moreover, continuous collaboration between chemical engineers, biopharmaceutical scientists, and production technologists is spurring the next wave of innovations in this field. As a result, stakeholders are now better equipped to balance efficacy with safety, paving the way for highly specialized pharmaceutical products that address complex therapies and patient needs. This evolving narrative sets the stage for a comprehensive exploration of market dynamics, segment-specific nuances, and strategic imperatives that guide industry players in a competitive and rapidly expanding environment.

Transformative Shifts in the Landscape of Biopharmaceutical Excipients

The landscape of biopharmaceutical excipients is undergoing transformative shifts as market dynamics influence innovation, efficiency, and regulatory compliance in unprecedented ways. Rapid technological advancements and enhanced production methodologies are fostering the creation of more pure and high-functionality compounds, driving product performance while ensuring stringent quality standards are met. There has been a noticeable transition from traditional, chemically derived components to novel formulations that combine advanced polymer science with enhanced bioactive characteristics. Shifts towards sustainable sourcing and greener production methods have also become focal points, as companies strive to balance economic growth with environmental responsibility. This evolution is bolstered by robust R&D investments and strategic collaborations across global research institutes and industry pioneers, which together promote cross-disciplinary insights into optimizing excipient functionality. Furthermore, an increased focus on personalized medicine and precision drug delivery has led to redesigned formulations that cater to specific therapeutic modalities and patient demographics. These transformative trends are setting the stage for a market characterized by continuous innovation and adaptive strategies, fundamentally reshaping how excipients contribute to pharmaceutical development. Consequently, the industry sees opportunities for differentiation, cost efficiency, and enhanced therapeutic outcomes that are instrumental for long-term success.

Key Segmentation Insights for a Nuanced Market Analysis

An in-depth segmentation analysis reveals a multifaceted approach to the biopharmaceutical excipients market that is both comprehensive and dynamic. When observed through the prism of product-based segmentation, the market is carved into specialized areas such as binders, coatings, diluents, disintegrants, lubricants and glidants, polyols, preservatives, solubilizers and surfactants/emulsifiers, along with suspending and viscosity agents. Within binders, further specificity is achieved through subdivisions like cellulosic binders, hydroxypropyl methylcellulose (HPMC), povidone (polyvinylpyrrolidone or PVP), as well as starch and modified starches. Similarly, coatings are studied across various types including controlled release, enteric, film, seal, and sugar coatings, while diluents encompass calcium phosphates, lactose, and microcrystalline cellulose. In the realm of polyols, the focus is on mannitol and sorbitol, and solubilizers and surfactants/emulsifiers are further dissected into esters, polysorbates, and triglycerides. Additionally, segmentation based on source differentiates natural from synthetic excipients. Further, formulation type segmentation spans injectable formulations-classified into intramuscular, intravenous, and subcutaneous-oral formulations including capsules, powders, and tablets, and topical formulations divided into creams, gels and ointments, and lotions. Last, end user segmentation addresses biopharmaceutical and pharmaceutical companies, contract manufacturers, and research institutes, all of which collectively provide a granular understanding across the full spectrum of market dynamics.

Based on Product, market is studied across Binders, Coatings, Diluents, Disintegrants, Lubricants & Glidants, Polyols, Preservatives, Solubilizers & Surfactants/Emulsifiers, and Suspending & Viscosity Agents. The Binders is further studied across Cellulosic Binders, Hydroxypropyl Methylcellulose (HPMC), Povidone (Polyvinylpyrrolidone or PVP), and Starch & Modified Starches. The Coatings is further studied across Controlled Release Coatings, Enteric Coatings, Film Coatings, Seal Coatings, and Sugar Coatings. The Diluents is further studied across Calcium Phosphates, Lactose, and Microcrystalline Cellulose. The Polyols is further studied across Mannitol and Sorbitol. The Solubilizers & Surfactants/Emulsifiers is further studied across Esters, Polysorbates, and Triglycerides.

Based on Source, market is studied across Natural Excipients and Synthetic Excipients.

Based on Formulation Type, market is studied across Injectable Formulations, Oral Formulations, and Topical Formulations. The Injectable Formulations is further studied across Intramuscular, Intravenous, and Subcutaneous. The Oral Formulations is further studied across Capsules, Powders, and Tablets. The Topical Formulations is further studied across Creams, Gels & Ointments, and Lotions.

Based on End User, market is studied across Biopharmaceutical & Pharmaceutical Companies, Contract Manufacturers, and Research Institutes.

Key Regional Insights Shaping Global Market Dynamics

A comprehensive regional analysis uncovers distinct trends and growth drivers tailored to diverse geographical markets. In the Americas, robust healthcare infrastructure and progressive regulatory frameworks serve as catalysts for innovation, enabling swift adoption of new technologies that improve therapeutic efficacy. Latin America, as a subset of this region, offers significant opportunities driven by growing investments in biopharmaceutical manufacturing and favorable government policies. Across the broad expanse of Europe, the Middle East, and Africa, there exists a blend of mature markets and emerging economies. In Europe, stringent quality standards and pioneering research activities facilitate the continuous evolution of excipient applications, while markets within the Middle East and Africa are beginning to harness the benefits of modern pharmaceutical practices. Meanwhile, the Asia-Pacific region is distinguished by rapid industrial expansion, rising investments in healthcare, and an increasing demand for cost-efficient yet high-quality pharmaceutical components. This geographical diversity not only underscores the importance of localized insights but also reflects the varied pace of technological adoption and market maturation across continents, each contributing uniquely to the accelerated growth of biopharmaceutical excipients on the global stage.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Fueling Market Innovation

The competitive arena in biopharmaceutical excipients is marked by the presence of several leading companies that consistently push the boundaries of innovation and quality. Industry leaders such as ABITEC Corporation, Actylis, Asahi Kasei Corporation, and Ashland Inc. are continually refining production techniques to enhance product efficacy and regulatory compliance. Company profiles extend to organizations like Avantor, Inc., BASF SE, Clariant International Ltd., and Colorcon Ltd., which leverage deep technical expertise and comprehensive R&D investments to drive market expansion. Further, Croda International PLC, DFE Pharma GmbH & Co KG, and Eastman Chemical Company have all demonstrated a strong commitment to sustainability and process optimization. In addition, the contributions of Evonik Industries AG, Fuji Chemical Industries Co., Ltd., IMCD N.V., Innophos Holdings, Inc., and International Flavors & Fragrances Inc. underscore a dedicated pursuit of novel excipient applications. Other significant players include JRS PHARMA GmbH + Co. KG, Kerry Group PLC, Meggle Group GmbH, Merck KGaA, Mitsubishi Chemical Group Corporation, NOF Corporation, Novo Nordisk A/S, Pfanstiehl, Inc., and Roquette Freres S.A., complemented by the innovative strides made by Shin-Etsu Chemical Co., Ltd., Sigachi Industries Limited, Spectrum Laboratory Products, Inc., SPI Pharma, Inc., By Associated British Foods, The Archer-Daniels-Midland Company, The Dow Chemical Company, The Lubrizol Corporation, and Wacker Chemie AG. Their strategic investments and domain expertise are instrumental in setting market benchmarks and driving cohesive progress.

The report delves into recent significant developments in the Biopharmaceutical Excipients Market, highlighting leading vendors and their innovative profiles. These include ABITEC Corporation, Actylis, Asahi Kasei Corporation, Ashland Inc., Avantor, Inc., BASF SE, Clariant International Ltd., Colorcon Ltd., Croda International PLC, DFE Pharma GmbH & Co KG, Eastman Chemical Company, Evonik Industries AG, Fuji Chemical Industries Co., Ltd., IMCD N.V., Innophos Holdings, Inc., International Flavors & Fragrances Inc., JRS PHARMA GmbH + Co. KG, Kerry Group PLC, Meggle Group GmbH, Merck KGaA, Mitsubishi Chemical Group Corporation, NOF Corporation, Novo Nordisk A/S, Pfanstiehl, Inc., Roquette Freres S.A., Shin-Etsu Chemical Co., Ltd., Sigachi Industries Limited, Spectrum Laboratory Products, Inc., SPI Pharma, Inc. By Associated British Foods, The Archer-Daniels-Midland Company, The Dow Chemical Company, The Lubrizol Corporation, and Wacker Chemie AG. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to embrace a proactive approach by investing in research and development aimed at increasing both the performance and safety profiles of biopharmaceutical excipients. Strategic collaborations with academic institutions and technology innovators can facilitate pilot projects that evaluate novel material properties and process improvements. It is recommended that companies undertake robust risk assessments to align with evolving regulatory frameworks and consumer expectations, while simultaneously exploring sustainable sourcing practices to reduce environmental impact. By incorporating advanced analytics in trend forecasting and supply chain optimization, organizations can maintain a competitive edge in an increasingly dynamic market. Enhancing interdepartmental collaboration and leveraging digital transformation will further streamline decision-making processes, ultimately driving significant improvements in operational efficiency and product innovation.

Conclusion: Navigating a Future of Unprecedented Growth

The biopharmaceutical excipients market is at a pivotal juncture where innovation meets traditional expertise. Continuous advancements in formulation science, process optimization, and sustainable practices signal a future rich with growth potential. This dynamic environment calls for strategic foresight and adaptable business models that can meet the demands of a rapidly evolving therapeutic landscape. With an emphasis on quality, efficiency, and actionable insights derived from thorough segmentation and regional analyses, industry stakeholders are well-positioned to harness emerging opportunities. The journey forward will depend upon a commitment to innovation and a clear understanding of the intricate interplay between technology, market demands, and regulatory considerations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases necessitating advanced drug formulations globally
      • 5.1.1.2. Rising FDA approvals and research activities in biopharmaceutical excipients
      • 5.1.1.3. Growing preference for multifunctional excipients offering enhanced drug stability and efficacy
    • 5.1.2. Restraints
      • 5.1.2.1. High development costs and availability of counterfeit and substandard excipients
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in research and development for innovative excipients to support large molecule drugs
      • 5.1.3.2. Partnerships & collaborations to enhance excipient supply chains and distribution
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities of regulatory compliance for excipients in the biopharmaceutical industry
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Versatile role of polyols in enhancing stability and functionality of biopharmaceutical formulations
    • 5.2.2. Formulation Type: Increasing adoption of excipients in oral formulations to ensure content stability
    • 5.2.3. Source: Growing preference for natural excipients for their biocompatibility and renewable nature
    • 5.2.4. End User: Rising utilization excipients across biopharmaceutical & pharmaceutical companies for innovative drug formulations
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biopharmaceutical Excipients Market, by Product

  • 6.1. Introduction
  • 6.2. Binders
    • 6.2.1. Cellulosic Binders
    • 6.2.2. Hydroxypropyl Methylcellulose (HPMC)
    • 6.2.3. Povidone (Polyvinylpyrrolidone or PVP)
    • 6.2.4. Starch & Modified Starches
  • 6.3. Coatings
    • 6.3.1. Controlled Release Coatings
    • 6.3.2. Enteric Coatings
    • 6.3.3. Film Coatings
    • 6.3.4. Seal Coatings
    • 6.3.5. Sugar Coatings
  • 6.4. Diluents
    • 6.4.1. Calcium Phosphates
    • 6.4.2. Lactose
    • 6.4.3. Microcrystalline Cellulose
  • 6.5. Disintegrants
  • 6.6. Lubricants & Glidants
  • 6.7. Polyols
    • 6.7.1. Mannitol
    • 6.7.2. Sorbitol
  • 6.8. Preservatives
  • 6.9. Solubilizers & Surfactants/Emulsifiers
    • 6.9.1. Esters
    • 6.9.2. Polysorbates
    • 6.9.3. Triglycerides
  • 6.10. Suspending & Viscosity Agents

7. Biopharmaceutical Excipients Market, by Source

  • 7.1. Introduction
  • 7.2. Natural Excipients
  • 7.3. Synthetic Excipients

8. Biopharmaceutical Excipients Market, by Formulation Type

  • 8.1. Introduction
  • 8.2. Injectable Formulations
    • 8.2.1. Intramuscular
    • 8.2.2. Intravenous
    • 8.2.3. Subcutaneous
  • 8.3. Oral Formulations
    • 8.3.1. Capsules
    • 8.3.2. Powders
    • 8.3.3. Tablets
  • 8.4. Topical Formulations
    • 8.4.1. Creams
    • 8.4.2. Gels & Ointments
    • 8.4.3. Lotions

9. Biopharmaceutical Excipients Market, by End User

  • 9.1. Introduction
  • 9.2. Biopharmaceutical & Pharmaceutical Companies
  • 9.3. Contract Manufacturers
  • 9.4. Research Institutes

10. Americas Biopharmaceutical Excipients Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biopharmaceutical Excipients Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biopharmaceutical Excipients Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Nucleus Biologics secures EXCiPACT certification to enhancing quality and compliance in biopharmaceutical excipients
    • 13.3.2. Nagase Viita to launch injectable-grade SUCROSE SG in 2025
    • 13.3.3. Ashland launch innovative excipient solutions to enhance pharmaceutical formulations at CPHI Milan and AAPS PharmSci 360
    • 13.3.4. VION Biosciences expands lipid capabilities with acquisition of Echelon Biosciences
    • 13.3.5. Roquette to acquire IFF Pharma Solutions to strengthen its position in the biopharmaceutical excipients market
    • 13.3.6. Azelis expands biopharmaceutical portfolio through partnership with Anhui Sunhere
    • 13.3.7. Barentz enters U.S. distribution agreement for Ashland's vialose parenteral excipient
    • 13.3.8. BASF and IFF collaborate to enhance formulation efficiency with ZoomLab integration
    • 13.3.9. Roquette launch advanced excipient grades for enhanced moisture protection at CPHI Barcelona
    • 13.3.10. Clariant launch innovative high-purity excipients to enhance API stability and solubility at CPHI Barcelona
    • 13.3.11. Ingredion expands pharmaceutical excipients portfolio with strategic acquisitions in India
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Ashland Inc.
    • 13.4.2. Croda International PLC
    • 13.4.3. Clariant International Ltd.
    • 13.4.4. BASF SE

Companies Mentioned

  • 1. ABITEC Corporation
  • 2. Actylis
  • 3. Asahi Kasei Corporation
  • 4. Ashland Inc.
  • 5. Avantor, Inc.
  • 6. BASF SE
  • 7. Clariant International Ltd.
  • 8. Colorcon Ltd.
  • 9. Croda International PLC
  • 10. DFE Pharma GmbH & Co KG
  • 11. Eastman Chemical Company
  • 12. Evonik Industries AG
  • 13. Fuji Chemical Industries Co., Ltd.
  • 14. IMCD N.V.
  • 15. Innophos Holdings, Inc.
  • 16. International Flavors & Fragrances Inc.
  • 17. JRS PHARMA GmbH + Co. KG
  • 18. Kerry Group PLC
  • 19. Meggle Group GmbH
  • 20. Merck KGaA
  • 21. Mitsubishi Chemical Group Corporation
  • 22. NOF Corporation
  • 23. Novo Nordisk A/S
  • 24. Pfanstiehl, Inc.
  • 25. Roquette Freres S.A.
  • 26. Shin-Etsu Chemical Co., Ltd.
  • 27. Sigachi Industries Limited
  • 28. Spectrum Laboratory Products, Inc.
  • 29. SPI Pharma, Inc. By Associated British Foods
  • 30. The Archer-Daniels-Midland Company
  • 31. The Dow Chemical Company
  • 32. The Lubrizol Corporation
  • 33. Wacker Chemie AG

LIST OF FIGURES

  • FIGURE 1. BIOPHARMACEUTICAL EXCIPIENTS MARKET MULTI-CURRENCY
  • FIGURE 2. BIOPHARMACEUTICAL EXCIPIENTS MARKET MULTI-LANGUAGE
  • FIGURE 3. BIOPHARMACEUTICAL EXCIPIENTS MARKET RESEARCH PROCESS
  • FIGURE 4. BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. BIOPHARMACEUTICAL EXCIPIENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICAL EXCIPIENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOPHARMACEUTICAL EXCIPIENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSIC BINDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE (HPMC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POVIDONE (POLYVINYLPYRROLIDONE OR PVP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCH & MODIFIED STARCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CONTROLLED RELEASE COATINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ENTERIC COATINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FILM COATINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SEAL COATINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGAR COATINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CALCIUM PHOSPHATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LACTOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DISINTEGRANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LUBRICANTS & GLIDANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MANNITOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SORBITOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRESERVATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ESTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYSORBATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TRIGLYCERIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUSPENDING & VISCOSITY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY NATURAL EXCIPIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SYNTHETIC EXCIPIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GELS & OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LOTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BIOPHARMACEUTICAL & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CONTRACT MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 228. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 239. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 240. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 263. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 264. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 266. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 267. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 274. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 275. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 276. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 278. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 279. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 280. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 285. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 286. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 287. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 288. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 290. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 291. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 292. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
  • TABLE 309. DENMARK BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY D